Clinical trials: Chronic Cough
Cough
Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 619734 in subjects with chronic cough from an unknown cause.
- Trial name
- NCT00506545
- Testing
- SCH 619734
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
- Trial name
- NCT00103922
- Testing
- cilomilast
- Where
- 115 sites in United States
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
Refractory Chronic Cough
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- SOOTHE (NCT04678206)
- Testing
- BLU-5937
- Where
- 116 sites in United States, Canada and 5 more
- Volunteers
- 310 people
- Sponsor
- Bellus Health Inc. - a GSK company
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Lung Diseases, Interstitial
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this study is to investigate the correlation between changes from baseline to 52 weeks in Forced Vital Capacity (FVC) [% pred.] and changes from baseline to 52 weeks in dyspnea score [points] or cough…
- Trial name
- NCT05151640
- Testing
- Nintedanib
- Where
- 31 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 158 people
- Sponsor
- Boehringer Ingelheim
Chronic Cough
A Dose Escalation Study of Bradanicline in Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, crossover, dose escalation study of bradanicline in subjects with chronic cough
- Trial name
- NCT03622216
- Testing
- Bradanicline
- Where
- 17 sites in United States
- Volunteers
- 46 people
- Sponsor
- Attenua, Inc.
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- OCEAN-1 (NCT07671911)
- Testing
- NAL ER
- Where
- 22 sites in United States
- Volunteers
- 306 people
- Sponsor
- Trevi Therapeutics
Drug Interactions
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy…
- Trial name
- NCT04252300
- Testing
- Rosuvastatin, Rosuvastatin + BAY1817080
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Cough
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension
The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period.
- Trial name
- NCT04525885
- Testing
- Gefapixant 45 mg twice daily (BID), Gefapixant 15 mg BID, Gefapixant 45 mg BID
- Where
- 8 sites in China
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Cough
A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic cough designed to evaluate the effectiveness of…
- Trial name
- EPICC (NCT01432730)
- Testing
- Gefapixant
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds 2
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood acute respiratory disease, including pneumonia, bronchiolitis, asthma/reactive airways disease…
- Conditions
- Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup
- Trial name
- SMARTCOUGH-C-2 (NCT03392363)
- Testing
- Recordings of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,470 people
- Sponsor
- ResApp Health Limited
Refractory Chronic Cough
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
The primary objective of this double-blind crossover study is to assess the effect of single doses of 50 mg and 300 mg gefapixant (AF-219/MK-7264) on cough reflex sensitivity to capsaicin in both healthy participants and…
- Trial name
- NCT02397460
- Testing
- Gefapixant
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
- Trial name
- NCT02612623
- Testing
- Gefapixant
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cough
Study of the Safety and Effectiveness of BC1036 Capsules to Treat Frequent Long-Term Cough
The purpose of this study is to investigate the effect of BC1036 (theobromine) on cough-related quality of life and cough severity following 2 weeks' treatment.
- Trial name
- NCT01656668
- Testing
- BC1036
- Where
- 13 sites in United Kingdom
- Volunteers
- 288 people
- Sponsor
- Respicopea Limited
Refractory Chronic Cough
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- CALM-2 (NCT07650084)
- Testing
- BLU-5937
- Where
- 38 sites in China
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Chronic Refractory Cough
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
- Trial name
- RELIEF (NCT03979638)
- Testing
- BLU-5937
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Bellus Health Inc. - a GSK company
Chronic Idiopathic Cough
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic idiopathic cough.
- Trial name
- NCT02233699
- Testing
- XEN-D0501
- Where
- 2 sites in Ireland, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Xention Ltd
Refractory Chronic Cough
A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib/II clinical trial to evaluate the effectiveness, safety, tolerability and pharmacokinetics (PK) of TCR1672 Tablets in patients with refractory…
- Trial name
- NCT06213363
- Testing
- TCR1672 tablet
- Volunteers
- 72 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Cough
Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients
To investigate the safety and tolerability of ascending repeated oral doses of BAY1817080 in healthy volunteers(Part1). To investigate the safety, tolerability and efficacy of BAY1817080 in patients with refractory chronic…
- Trial name
- NCT03310645
- Testing
- BAY1817080
- Where
- 7 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Bayer
Cough, Refractory Chronic Cough
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- CALM-2 (NCT05600777)
- Testing
- BLU-5937
- Where
- 242 sites in United States, Australia and 11 more
- Volunteers
- 997 people
- Sponsor
- Bellus Health Inc. - a GSK company